Connor TH, Anderson RW, Sessink PJ, Spivey SMEffectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm2002; 59: 68—72.
2.
Gustavsson B.Evaluation of technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract1997; 3: 46.
3.
Harrison BR, Peters BG, Bing MRComparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques . Am J Health Syst Pharm2006; 63: 1736—44.
4.
NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No 2004—165.
5.
Nygren O., Gustavsson B., Strom L., Eriksson R., Jarneborn L., Friberg A.Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and closed system. J Environ Monit2002; 4: 739—42.
6.
Nygren O., Gustavsson B., Ström L., Friberg A.Cisplatin contamination observed on the outside of drug vials. Ann Occup Hyg2002; 46(6): 555—57.
7.
Poirier S., Jones C., Calvert MJPractical implementation of a closed system (PhaSeal) for the preparation,administration and disposal of cytotoxic drugs in a busy ambulatory cancer centre. J Oncol Pharm Pract2004; 10(2): 81.
8.
Sessink Pjm, Rolf M-AE, Ryden NSEvaluation of the PhaSeal hazardous drug containment system. Hosp Pharm1999; 34: 1311—17.
9.
Spivey S., Connor THDetermining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm2003; 38(2): 135—39.
10.
Tans B., Willems L.Comparative contamination study with cyclophosphamide, fluorouracil and ifosfamide: standard technique versus a proprietary closed-handling system. J Oncol Pharm Pract2004; 10: 217—23.
11.
Vandenbroucke J., Robays H.How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract2001; 6(4): 146—52.
12.
Wick C., Slawson MH, Jorgenson JA, Tyler LSUsing a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314—20.
